San Diego, CA -- (SBWire) -- 01/19/2023 --Design Therapeutics, Inc. is under investigation over potential securities laws violations.
Investors who purchased shares of Design Therapeutics, Inc. (NASDAQ: DSGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Design Therapeutics, Inc. (NASDAQ: DSGN) concerning whether a series of statements by Design Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Carlsbad, CA based Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. On or around March 24, 2021, Design Therapeutics, Inc. conducted its initial public offering ("IPO"), selling 12 million shares of stock priced at $20.00 per share.
Then, on December 7, 2022, Design Therapeutics, Inc. reported initial data from a Phase 1 trial of DT-216 in patients with Friedreich ataxia. Among other results, Design said 16 patients on DT-216 and eight on placebo reported at least one treatment-emergent adverse event.
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN) declined from $24.85 per share on August 09, 2022, to as low as $6.94 per share on December 08, 2022.
Those who purchased shares of Design Therapeutics, Inc. (NASDAQ: DSGN) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws
An investigation for investors in Design Therapeutics, Inc. (NASDAQ:DSGN) shares over potential securities laws violations by Design Therapeutics, Inc. was announced.